APA (7th ed.) Citation

Branford, S., Kim, D., Soverini, S., Haque, A., Shou, Y., Woodman, R. C., . . . Müller, M. C. (2012). Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. Journal of clinical oncology, 30(35), 4323-4329. https://doi.org/10.1200/JCO.2011.40.5217

Chicago Style (17th ed.) Citation

Branford, Susan, et al. "Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib." Journal of Clinical Oncology 30, no. 35 (2012): 4323-4329. https://doi.org/10.1200/JCO.2011.40.5217.

MLA (9th ed.) Citation

Branford, Susan, et al. "Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib." Journal of Clinical Oncology, vol. 30, no. 35, 2012, pp. 4323-4329, https://doi.org/10.1200/JCO.2011.40.5217.